Fivetran Launches Hybrid Deployment, Enabling Enterprises to Run Pipelines in Any Environment on a Unified Platform
Hybrid Deployment offers a secure, flexible solution for seamless data movement across environments
Fivetran, the global leader in data movement, today announced Hybrid Deployment, a new solution that allows customers to securely run data pipelines within their own environment from the Fivetran managed platform, providing a single control plane to manage all data sources, whether they are cloud-based SaaS apps or legacy databases with data that needs to be tightly controlled and managed for regulatory or compliance purposes. With the industry’s most comprehensive selection of connectors, destinations and features, Fivetran empowers enterprises to centralize data efficiently, reliably and securely, while supporting governance and compliance requirements and benefiting from 24/7 support.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240918100338/en/
Introducing Fivetran’s Hybrid Deployment: A fully managed service that meets the highest enterprise security standards. (Graphic: Business Wire)
Enterprises with sensitive data or in regulated industries often struggle to build data-driven practices. Seamless data access is critical for boosting efficiency, enabling AI-powered analytics and producing reliable data products. Centralizing data can lead to complex, costly systems that burden engineering teams. Traditional SaaS tools often lack the needed control and security, forcing organizations into more cumbersome solutions. DIY or self-hosted solutions often fail to scale effectively, especially as data priorities evolve in the age of AI, resulting in inefficiencies and an urgent need for modernization. Fivetran’s Hybrid Deployment simplifies this by enabling businesses to securely centralize their data and prepare it for AI and machine learning, all while maintaining control over sensitive information.
"Introducing a hybrid cloud deployment model to the Fivetran platform opens up entirely new possibilities for businesses of all sizes," said George Fraser, Fivetran CEO. "Businesses no longer have to choose between managed automation and data control. They can now securely move data from all their critical sources—like Salesforce, Workday, Oracle, SAP, other cloud and on-premises databases and ERPs—into a data warehouse or data lake, all while keeping that data under their own control. This is especially valuable for industries like healthcare and life sciences and financial services, where secure, compliant and reliable data is critical."
How Hybrid Deployment works
Hybrid Deployment keeps sensitive data within the customer’s environment while taking advantage of Fivetran’s management and monitoring tools. A lightweight local connector securely moves the data, while Fivetran’s user-friendly interface makes configuration and monitoring simple, all from a single control plane.
"Fivetran's new hybrid deployment option is a game-changer. Now customers can easily centralize all their data, regardless of security or compliance requirements, given the ability to separate the control and data plane,” said Vinay Kumar Katta, Managing Delivery Architect, Capgemini. “Customers will appreciate Fivetran's best-in-class platform that offers the flexibility to choose how and where their pipelines run. We're excited to advance our partnership with Fivetran and help more enterprises modernize their data infrastructure."
The separate control and data plane architecture ensures data never leaves the customer’s secure environment, giving them ultimate control over how their data is moved while still benefiting from Fivetran’s managed platform. This solution automates and centralizes the data movement process, while also giving enterprises the benefits of:
- Full visibility: Monitor all pipelines from a single interface.
- Data security: Control access, mask sensitive data and track movement to ensure compliance.
- Compatibility across environments: Works across AWS, Microsoft Azure, Google Cloud, and on-premises environments.
- Simple setup: Quick installation with no complex maintenance required.
- Flexibility: Scale and customize pipelines with integrations for APIs and tools like Terraform.
- Cost management: Track usage and control budgets with detailed reporting tools.
"phData is excited about Fivetran's new Hybrid Deployment option, which allows our customers in regulated industries like healthcare, life sciences and financial services to scale the configuration and ingestion of highly sensitive datasets on self-managed infrastructure," said Troy Fokken, Chief Architect at phData. "This approach streamlines the data pipeline processes, as customers don't need to self-host software or build DIY pipelines to securely move data from source systems to destination."
As government regulations like GDPR, HIPAA and CCPA continue to tighten, and new ones emerge, enterprises are increasingly focused on ensuring their data practices meet strict security and compliance standards. Recent breaches in healthcare and financial services have highlighted the risks of exposing sensitive information and compromising critical systems. DIY or self-managed pipelines can introduce vulnerabilities, especially as teams must frequently make updates in order to meet rapidly changing data schema, which increases the risk of errors that can lead to data breaches. Fivetran’s Hybrid Deployment mitigates these risks by providing a managed solution that runs within the customer’s secure environment, ensuring compliance while eliminating common points of failure.
“The simplicity of management is the best value of Hybrid Deployment,” said Ajay Bidani, Data and Insights Manager at Powell Industries. “I know the status of our pipelines and can launch and manage cloud-based and on-premises pipelines directly from one platform. Given our history with on-premises applications, I can say that pipelines going down and requiring restart was quite cumbersome, but Hybrid Deployment has been considerably different. I can realize the ease of monitoring and maintaining pipelines with immediacy. The ability to quickly stand up Hybrid Deployment for on-premises data movement, while managing it from a straightforward and familiar cloud-based control plane, is a great value add.”
Reducing complexity for engineering teams
Hybrid Deployment reduces manual setup and maintenance, allowing engineering teams to focus on building data-driven solutions. Fivetran handles the heavy lifting, helping businesses extract value from their data without worrying about brittle DIY infrastructure. A recent report by IDC found that enterprises can realize an average annual productivity gain of $1.5 million by transitioning to Fivetran’s managed data movement solution.
Fivetran’s data integration platform can handle high-volume change data capture from databases and offers 600+ pre-built connectors for a range of SaaS applications, events, files, ERPs, data warehouses and data lakes. The Fivetran platform replicates data with minimal impact on source systems, low latency and high throughput, making it the trusted choice for over 6,300 customers globally. With the richest technical feature set of any data ingestion tool, Fivetran meets the widest range of data integration use cases.
To learn more, visit the Fivetran blog or explore images and assets in the Fivetran newsroom. You can also start your free Hybrid Deployment trial today at Fivetran.com.
About Fivetran
Fivetran, the global leader in data movement, helps customers use their data to power everything from AI applications and ML models, to predictive analytics and operational workloads. The Fivetran platform reliably and securely centralizes data from hundreds of SaaS applications and databases into any cloud destination — whether deployed on-premises, in the cloud or in a hybrid environment. Thousands of global brands, including Autodesk, Condé Nast, JetBlue and Morgan Stanley, trust Fivetran to move their most valuable data assets to fuel analytics, drive operational efficiencies and power innovation. For more info, visit fivetran.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240918100338/en/
Contacts
Matias Cavallin
Matias Cavallin
323-715-0020
matias.cavallin@fivetran.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in Phlebotomy, Improved Hematocrit Control in Polycythemia Vera1.6.2025 14:00:00 CEST | Press release
Rusfertide plus current standard of care more than doubled clinical response rates across high- and low-risk PV groups, significantly reducing phlebotomy eligibility compared to placebo plus current standard of care, which was the primary endpointAll key secondary endpoints met with statistical significance, including a nearly three-fold reduction in the proportion of patients requiring phlebotomy and a four-fold improvement in hematocrit control in rusfertide arm compared to placebo arm, as well as improvements in patient-reported outcomesNo serious adverse events considered related to rusfertide were reportedRusfertide has received Orphan Drug designation and Fast Track designation from the U.S. FDA Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announced detailed results from the Phase 3, randomized, placebo-controlled VERIFY study evaluating rusfertide in patients with polycythemia vera (PV), which met the primary and all key secondary e
BeOne Medicines Presents New SEQUOIA Study Results Reinforcing BRUKINSA’s Differentiated Profile with or without Venetoclax in Frontline CLL at ASCO 202531.5.2025 14:00:00 CEST | Press release
BRUKINSA plus venetoclax demonstrated high response rates and a favorable safety profile across CLL patient types in SEQUOIA Arm D, including those with high-risk del(17p) mutational statusAt 5-year follow-up of SEQUOIA Arm C, BRUKINSA monotherapy showed sustained OS and PFS benefit in hard-to-treat del(17p) CLL patients versus historical data BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today will present new data from the Arm C and D cohorts of the pivotal, global Phase 3 SEQUOIA trial of BRUKINSA® (zanubrutinib). The findings underscore the strong and consistent efficacy of BRUKINSA across CLL patient types, including high-risk mutation status. These data will be presented in two rapid oral presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL. Data from the Arm D of SEQUOIA demonstrate that treatment with BRUKINSA plus venetoclax has the potential to drive progression-free survival and overall dee
Andersen Consulting tilføjer Stratence Partners30.5.2025 16:07:00 CEST | Pressemeddelelse
Andersen Consulting udvider sin platform med en samarbejdsaftale med Stratence Partners, der er et konsulentfirma med base i Storbritannien, som hjælper globale virksomheder med at øge markedsandele og forbedre rentabiliteten gennem deres ekspertise inden for prisfastsættelse, strategisk optimering, kommerciel effektivitet og digital transformation. Stratence Partners har en resultatorienteret tilgang og er forpligtet på bæredygtig forandring, hvorved de hjælper deres kunder gennem en unik kombination af konsulentbistand, midlertidige ledelsesindsater og oplæringskurser samt deres egne metoder og løsninger inden for datastyring, datavidenskab (AI), værktøjer og systemer. "Samarbejdet med Andersen Consulting er et spændende skridt for vores firma," sagde Fernando Ventureira, administrerende direktør for Stratence Partners. "I vores arbejde med hos ledere over hele verden har vi erfaret, at deres behov rækker ud over strategisk prisfastsættelse og driftsoptimering. Vores kunder værdsætte
You Up? Grindr’s “Right Now” Goes Global30.5.2025 15:00:00 CEST | Press release
More places, more people – Grindr’s real-time hookup feature makes connecting faster than ever Grindr, the Global Gayborhood in Your Pocket™ with more than 14.6M average monthly active users, today announced the global launch of Right Now, their newest intent-based feature designed to instantly connect people looking for immediate encounters. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250530651954/en/ Grindr's Right Now feature. Right Now is a real-time feed—separate from the app’s main grid that displays profiles—where Grindr users can post text and share photos displayed for one hour, letting other like-minded users know exactly what they’re looking for. “Right Now empowers our users to find exactly what they want, when they want it – without the guesswork,” said AJ Balance, Chief Product Officer at Grindr. “We built this intention-based feature based on feedback from our community so they can connect with like-minded
CAR T Vision Coalition Launches with Ambitious Goal to Double Patients Treated with the Curative Potential of CAR T-cell Therapy by 203030.5.2025 14:00:00 CEST | Press release
Only approximately 2 out of 10 people in the US and 3 out of 10 people in Europe with certain rare, advanced blood cancers receive access to CAR T-cell therapy1,2,3New roadmap report aims to inspire collective action of stakeholder groups and invites additional CAR T-cell therapy leaders to join the coalition Today an international coalition announces the launch of CAR T Vision to unite stakeholders around the shared ambition that every eligible patient should have the opportunity for cure with CAR T-cell therapy. By 2030, the aim is to double the proportion of eligible patients treated with CAR T-cell therapy. As outlined in the new roadmap report, the coalition will work to address access challenges and drive meaningful change in the CAR T-cell therapy healthcare ecosystem with a focus on three critical priorities: increasing awareness and understanding of CAR T-cell therapy; expanding resources and capacity to deliver CAR T-cell therapy; and developing sustainable and innovative fin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom